A 4-year-old boy presents with honey-crusted lesions on his face and forearms for 3 days. Lesions started as pustules and progressed to crusted plaques. He attends a local school and shares towels with other children. On examination, there is no lymphadenopathy or systemic toxicity. What is the most appropriate next step in management?

Explanation

## Clinical Assessment This is a classic presentation of **non-bullous impetigo** — the most common form of impetigo in children. Key features are: - Honey-crusted lesions (pathognomonic) - Rapid progression from pustules to crusted plaques - Localized, non-systemic disease - No signs of systemic toxicity or complications ## Management Algorithm for Impetigo ```mermaid flowchart TD A[Impetigo diagnosed]:::outcome --> B{Extent and severity?}:::decision B -->|Localized, <2% BSA, non-systemic| C[Topical antibiotics]:::action B -->|Extensive >2% BSA or systemic signs| D[Oral antibiotics]:::action B -->|Bullous or complicated| E[Oral + consider IV antibiotics]:::action C --> F[Mupirocin 2% TID x 7 days]:::action D --> G[Cephalexin or Cloxacillin]:::action E --> H[Hospitalization + IV therapy]:::urgent ``` ## Treatment Guidelines **First-line for localized impetigo:** **Key Point:** Topical mupirocin is the gold standard for localized, non-bullous impetigo affecting <2% body surface area (BSA) with no systemic involvement. | Feature | Topical Mupirocin | Oral Antibiotics | |---------|------------------|------------------| | **Indication** | Localized (<2% BSA), non-systemic | Extensive (>2% BSA) or systemic signs | | **Efficacy** | 95% cure rate for localized disease | Better for widespread lesions | | **Duration** | 7 days, 3 times daily | 7–10 days | | **Resistance risk** | Low if used appropriately | Slightly higher with prolonged use | | **Cost** | Moderate | Low to moderate | **High-Yield:** In this case, the lesions are localized to face and forearms (clearly <2% BSA), there is no lymphadenopathy, and the child is systemically well. Topical therapy is sufficient and is the preferred first-line approach per international guidelines (AAD, IDSA, WHO). ## Why Oral Antibiotics Are Not First-Line Here **Clinical Pearl:** Oral antibiotics are reserved for: - Impetigo affecting >2% BSA - Facial impetigo near the eyes (risk of spread) - Systemic signs (fever, lymphadenopathy) - Immunocompromised patients - Failure of topical therapy This patient does not meet these criteria. ## Antibiotic Choice (If Oral Therapy Were Needed) - **Cephalexin 500 mg QID × 7 days** — first-line oral agent (covers *S. aureus* and *S. pyogenes*) - **Cloxacillin** — alternative (not commonly used in India; cephalexin preferred) - **Clindamycin** — reserved for MRSA or penicillin allergy; not first-line for community impetigo ## Key Supportive Measures 1. Gentle cleansing of crusts with soap and water 2. Avoid sharing towels, clothing, or personal items 3. Keep nails trimmed to prevent spread by scratching 4. School exclusion until lesions are crusted or 48 hours of antibiotics given